The core strength of SEVER Life Sciences lies in the range of products and services our companies offer to patients and customers across the world.

Created as a holding company in 2019, Sever brings together four diverse but complementary companies, each with their own specialist focus. As a result, SEVER oversees an unrivalled and uniquely successful series of products, services and technologies.

SEVER and the four companies

Amring USA, Izvarino, Nordic Pharma and Sever Pharma Solutions are all united by a common purpose : a concern for patients.

Located across several continents and with markets across the globe, these companies work tirelessly to put the needs of patients first.

Amring

Sever

Izvarino

Nordic

Pharmaceutical

These companies
discover new drugs

for unmet medical needs ; they supply consistent, relevant and high-quality generic drugs ; and they develop, license and manufacture pharmaceutical products.

SEVER’s teams not only forge an all-round series of products and services, but also foster a hugely varied expertise

With an exchange of technologies, know-how, regulatory support and marketing tools, synergies are generated between the four companies, exploiting the rich talent and full potential of each of them. For instance, ‘Nordimet Pen’, an innovative product in the field of rheumatology, was partly developed, and is

manufactured by, Sever Pharma Solutions, and commercialized by Nordic Pharma. Similarly, Sever Pharma Solutions intends to deploy its sterile production centre – which obviates any concerns about contamination – to facilitate greater output of injectable products for both Nordic Pharma and Amring USA.

Very few companies the size of SEVER Life Sciences

can boast of being able to develop, register, manufacture, license, distribute and market their own pharmaceutical products. Equally, virtually no company of SEVER’s size has the same geographical reach. Our base is Europe but we also have a strong presence in Canada, Japan, Russia and the USA. Our international focus means that where others might see obstacles, we see opportunities.